Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 40
- 0 vs. Q3 2022
- Portfolio value
- $483.7M
- +$68.4M (+16.5%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| PCVXVaxcyte, Inc. | COM | 800,000 | $38.4M | 7.9% | +200,000+33.3% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 850,000 | $33.5M | 6.9% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,436,569 | $28.4M | 5.9% | +1,121,569+356.1% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 3,637,718 | $26.7M | 5.5% | +189,197+5.5% | Added | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,322,870 | $25.6M | 5.3% | +281,133+27.0% | Added | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 160,000 | $25.5M | 5.3% | −55,000−25.6% | Reduced | History |
| SGENSeagen Inc. | COM | 160,500 | $20.6M | 4.3% | +84,000+109.8% | Added | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,541,779 | $18.5M | 3.8% | −1,019,205−28.6% | Reduced | History |
| ISEEIVERIC bio, Inc. | COM | 825,000 | $17.7M | 3.7% | +825,000 | New | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,019,282 | $16.1M | 3.3% | 00.0% | Unchanged | History |
| HRTXHeron Therapeutics, Inc. | COM | 6,360,161 | $15.9M | 3.3% | +715,000+12.7% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 342,300 | $15.9M | 3.3% | +342,300 | New | History |
| OPTNOptiNose, Inc. | COM | 7,894,736 | $14.6M | 3.0% | +7,894,736 | New | History |
| VTYXVentyx Biosciences, Inc. | COM | 400,695 | $13.1M | 2.7% | +130,728+48.4% | Added | History |
| CINCCinCor Pharma, Inc. | COM | 1,019,153 | $12.5M | 2.6% | +717,829+238.2% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 1,295,034 | $12.2M | 2.5% | +1,295,034 | New | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 544,451 | $11.7M | 2.4% | +473,830+670.9% | Added | History |
| PTCTPTC Therapeutics, Inc. | COM | 302,135 | $11.5M | 2.4% | +302,135 | New | History |
| JBIOJade Biosciences, Inc. | COM | 378,522 | $11.1M | 2.3% | +378,522 | New | History |
| TVTXTravere Therapeutics, Inc. | COM | 475,000 | $9.99M | 2.1% | −491,108−50.8% | Reduced | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 1,550,000 | $9.72M | 2.0% | +750,561+93.9% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 73,000 | $9.46M | 2.0% | +73,000 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,055,801 | $7.14M | 1.5% | −495,918−32.0% | Reduced | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 190,000 | $7.02M | 1.5% | +190,000 | New | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 642,566 | $6.75M | 1.4% | +150,566+30.6% | Added | History |
| ERASErasca, Inc. | COM | 1,538,461 | $6.63M | 1.4% | +1,538,461 | New | History |
| ICPTIntercept Pharmaceuticals, Inc. | COM | 528,850 | $6.54M | 1.4% | +423,850+403.7% | Added | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,116,581 | $6.03M | 1.2% | −83,419−7.0% | Reduced | History |
| MRTXMirati Therapeutics, Inc. | COM | 133,000 | $6.03M | 1.2% | +133,000 | New | History |
| VERVVerve Therapeutics, Inc. | COM | 300,000 | $5.80M | 1.2% | +300,000 | New | History |
| ALBOAlbireo Pharma, Inc. | COM | 267,283 | $5.78M | 1.2% | +267,283 | New | History |
| LRMRLarimar Therapeutics, Inc. | COM | 1,273,635 | $5.26M | 1.1% | +138,635+12.2% | Added | History |
| URGNUroGen Pharma Ltd. | COM | 560,000 | $4.97M | 1.0% | −313,424−35.9% | Reduced | History |
| DTILPrecision Biosciences Inc | COM | 3,801,305 | $4.52M | 0.9% | +1,090,500+40.2% | Added | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 1,962,399 | $4.51M | 0.9% | +1,513,350+337.0% | Added | – |
| GBIOGeneration Bio Co. | COM | 1,022,537 | $4.02M | 0.8% | +197,460+23.9% | Added | History |
| EOLSEvolus, Inc. | COM | 190,329 | $1.43M | 0.3% | +190,329 | New | History |
| ALKSAlkermes plc. | SHS | 46,185 | $1.21M | 0.2% | −461,315−90.9% | Reduced | History |
| IMUXImmunic, Inc. | COM | 632,184 | $885.1K | 0.2% | +632,184 | New | History |
| ANABAnaptysbio, Inc | COM | 15,000 | $464.9K | 0.1% | +15,000 | New | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q3 2022 (15)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| RLMDRelmada Therapeutics, Inc. | COM | 510,000 | $18.9M | 4.5% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 306,411 | $13.1M | 3.1% | History |
| BBIOBridgeBio Pharma, Inc. | COM | 1,050,000 | $10.4M | 2.5% | History |
| TCDATricida, Inc. | COM | 870,000 | $9.12M | 2.2% | History |
| REPLReplimune Group, Inc. | COM | 390,000 | $6.74M | 1.6% | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 95,500 | $6.21M | 1.5% | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 674,656 | $6.20M | 1.5% | History |
| ETNB89bio, Inc. | COM | 955,000 | $5.53M | 1.3% | History |
| NGMNGM Biopharmaceuticals Inc | COM | 316,256 | $4.14M | 1.0% | History |
| IMCRImmunocore Holdings plc | ADS | 78,527 | $3.69M | 0.9% | History |
| Pieris Pharmaceuticals Inc720795103 | COM | 1,965,449 | $2.26M | 0.5% | – |
| DNTHDianthus Therapeutics, Inc. | COM | 1,019,091 | $1.44M | 0.3% | History |
| NKTRNektar Therapeutics | COM | 447,820 | $1.43M | 0.3% | History |
| SYRESpyre Therapeutics, Inc. | COM | 2,500,000 | $1.31M | 0.3% | History |
| SLNSilence Therapeutics plc | ADS | 68,915 | $692.0K | 0.2% | History |